撰文丨王聪 编辑丨王多鱼 排版丨水成文 结直肠癌 （Colorectal Cancer，CRC） 是全世界范围内发病人数第三的癌症 （近 200 万人，仅次于 肺癌 和 乳腺癌 ） ，死亡人数第二的癌症 （近 100 万 人，仅次于 肺癌 ） ， 结直肠癌在早期通常无症状，因此，诊断出来时往往已是晚期，因此需要手术、放疗和化疗等积极治疗。 然而，这些治疗方法也有局限性——手术复发率高，放 疗可引起严重并发症，化疗常导致耐药，约 50% 的患者会出现复发。此外，近 30 年来，50 岁以下的年轻人群中结直肠癌的发病率一直在上升。这使得结直肠 癌成为重大的公共卫生和社会经济问题。 2025 年 5 月 30 日， 赣南医科大学 张书永 教授、 郑勇 博士、 王烈峰 教授等在 Cell 子刊 Cell Reports Medicine 上发表了题为： Combined therapy with DR5-targeting antibody-drug conjugate and CDK inhibitors as a strategy for advanced colorectal cancer 的研究论文。 该研究 ...

Core Insights - Eli Lilly and Company is set to present data on several investigational drugs at the 2025 ASCO Annual Meeting, including imlunestrant, olomorasib, LY4170156, and Verzenio [1] Group 1: Imlunestrant (Investigational Oral SERD) - The company will present patient-reported outcomes from the Phase 3 EMBER-3 trial for patients with ER+, HER2- advanced breast cancer [2] - Expanded safety analyses from the EMBER-3 trial will also be featured in a poster presentation [2] Group 2: Olomorasib (Investigational KRAS G12C Inhibitor) - Updated results from a Phase 1/2 study of olomorasib will be reported, showing preliminary evidence of CNS activity in combination with pembrolizumab for KRAS G12C-mutant advanced NSCLC and with cetuximab for KRAS G12C-mutant colorectal cancer [3] - The presentations will utilize data cut-off dates of January 15, 2025, and November 13, 2024 [3] Group 3: LY4170156 (Investigational ADC Targeting FRα) - Initial results from a Phase 1a/1b study of LY4170156 in patients with platinum-resistant ovarian cancer will be presented [4] - The study involves a humanized monoclonal antibody linked to a topoisomerase I inhibitor [4] Group 4: Verzenio (Abemaciclib) - The impact of body mass index (BMI) on the efficacy and safety of Verzenio in breast cancer patients will be discussed [8] - Verzenio is an approved treatment for certain HR+, HER2- breast cancers and is available in multiple strengths [12][13]

Forward-Looking Statements Certain statements in this press release may be considered forward-looking statements. Forward-looking statements generally relate to future events, Tango's future operating performance and goals, the anticipated benefits of therapies and combination therapies (that include a Tango pipeline product), as well as the expectations, beliefs and development objectives for Tango's product pipeline and clinical trials. In some cases, you can identify forward-looking statements by termino ...